DUBAI — Roche Diagnostics, the diagnostic division of global healthcare company Roche, has planned to establish its Middle East regional headquarters at the Jebel Ali Free Zone, or Jafza, next month that will help the company to increase its market share in the region.
The announcement was made on the sidelines of healthcare exhibition and medical congress Arab Health in Dubai.
Although the company has been present in the region for more than 30 years, the regional headquarters in Jafza will be Roche Diagnostics’ first facility in the Middle East.
Through a strong distributor network, Roche Diagnostics has a presence in 18 markets in the region with a 20-25 per cent market share in all of these markets. Recognising the potential of the region, Roche Diagnostics seeks to increase the quality of supply and strengthen relations with distributors and end customers by providing added support and information.
In the UAE, Roche Diagnostics enjoys a continuous relationship with its long-term distributor Pharmatrade through 30 years.
“We believe Jafza’s unmatched connectivity, logistics and commercial advantages will support its growth in the region,” Jafza CEO and chief commercial officer Ibrahim Aljanahi said.
The new facility will be well positioned to serve the Roche’s growing customer base and help it further expand its regional footprint and market share, he added.
“The Middle Eastern region is a very important part of our business. We see a tremendous potential for growth in the Middle East. Therefore, we decided to open our regional headquarters in Dubai as a hub to serve our Middle Eastern countries... The unique combination of world-class port and airport facilities was one of the most significant reasons behind the decision to locate the Roche Diagnostics’ Middle East HQ in Jafza,” Roche Diagnostics Emea-Latam president Dr Michael Heuer said.
Jafza is one of the leading drivers in the UAE and Roche will benefit from the advantages that come with being part of a growing business community, Heuer said.